Intro: More than 15 years after the discovery of HIV-1 as the causative agent of AIDS, and numerous attempts to develop a vaccine, it has become clear that the efficacy of the currently considered HIV-1 vaccine candidates will generally be limited. This is at least in part due to the relative resistance of so-called primary HIV strains to neutralization by HIV-1 envelope specific antibodies: even the most potent HIV-1 neutralizing antibodies failed to provide protection in in vivo models, at concentrations that can be maintained for longer periods in human vaccinees.

, , , , , , , , , , , , , ,,
Erasmus MC: University Medical Center Rotterdam

Osterhaus, A., van Baalen, C., Gruters, R., Schutten, M., Siebelink, K., Hulskotte, E., … Sutter, G. (1999). Vaccination with Rev and Tat against AIDS. Vaccine, 17(20-21), 2713–2714. doi:10.1016/S0264-410X(98)00498-8